TYRA vs. BCYC, SAVA, ARQT, OCUL, INVA, LQDA, IRWD, CNTA, OPK, and ETNB
Should you be buying Tyra Biosciences stock or one of its competitors? The main competitors of Tyra Biosciences include Bicycle Therapeutics (BCYC), Cassava Sciences (SAVA), Arcutis Biotherapeutics (ARQT), Ocular Therapeutix (OCUL), Innoviva (INVA), Liquidia (LQDA), Ironwood Pharmaceuticals (IRWD), Centessa Pharmaceuticals (CNTA), OPKO Health (OPK), and 89bio (ETNB). These companies are all part of the "pharmaceutical preparations" industry.
Tyra Biosciences (NASDAQ:TYRA) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends, community ranking and analyst recommendations.
In the previous week, Tyra Biosciences had 14 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 20 mentions for Tyra Biosciences and 6 mentions for Bicycle Therapeutics. Tyra Biosciences' average media sentiment score of 0.70 beat Bicycle Therapeutics' score of 0.60 indicating that Tyra Biosciences is being referred to more favorably in the media.
Tyra Biosciences has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500.
Tyra Biosciences has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -404.14%. Tyra Biosciences' return on equity of -28.61% beat Bicycle Therapeutics' return on equity.
Bicycle Therapeutics received 102 more outperform votes than Tyra Biosciences when rated by MarketBeat users. Likewise, 68.57% of users gave Bicycle Therapeutics an outperform vote while only 62.07% of users gave Tyra Biosciences an outperform vote.
Tyra Biosciences has higher earnings, but lower revenue than Bicycle Therapeutics. Tyra Biosciences is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.
84.1% of Tyra Biosciences shares are owned by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are owned by institutional investors. 15.4% of Tyra Biosciences shares are owned by company insiders. Comparatively, 8.5% of Bicycle Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Tyra Biosciences currently has a consensus price target of $23.50, suggesting a potential upside of 27.58%. Bicycle Therapeutics has a consensus price target of $46.86, suggesting a potential upside of 111.93%. Given Bicycle Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than Tyra Biosciences.
Summary
Tyra Biosciences beats Bicycle Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Tyra Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for TYRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tyra Biosciences Competitors List
Related Companies and Tools
